^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Drug:Gazyva (obinutuzumab) (CD20 inhibitor) +
    Brukinsa (zanubrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    BeiGene Press Release
    Title:

    BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

    Published date:
    03/07/2024
    Excerpt:
    ...the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), in combination with the anti-CD20 monoclonal antibody obinutuzumab, after two or more lines of systemic therapy.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    BeiGene Press Release
    Title:

    https://ir.beigene.com/news/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment-of-relapsed-or-refractory/cccb4985-af95-4002-9f1a-1ddd39eb3ca1/

    Published date:
    11/17/2023
    Excerpt:
    BeiGene...announced that the European Commission (EC) has granted marketing authorization for BRUKINSA® (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior lines of systemic therapy.